Mereo BioPharma COVID-19 Information
Last Updated: 02-Oct-2020
Our foremost concerns at Mereo are to respect both the health of the osteogenesis imperfecta (“OI”) and alpha-1 antitrypsin deficiency (“Alpha") communities and all our clinical trial participants across our portfolio, as well as to acknowledge the pressures that healthcare systems are currently facing due to the ongoing COVID-19 pandemic. Our thoughts go out to the people and families directly impacted by this continuing public health crisis; as well as to the healthcare workers in the frontline, taking care of those affected.
Our current activities on setrusumab for the potential treatment of OI are focussed on preparations for the Phase 3 paediatric trial, which we are intending to start in Q1-2021. Patients who enrolled in our Phase 2b ASTEROID study in adults with OI are in a 1-year follow-up post-treatment extension phase, and the investigators leading this programme are continuing to take every care and to address each person on an individual basis to secure that safety and health are their primary concerns as we come to the end of this follow-up period of the study.
Our Phase 2 alvelestat trial is recruiting individuals with alpha-1 antitrypsin deficiency-related lung disease, who are potentially at greater risk from COVID-19 exposure. We have been in contact with the investigators with Alphas in their trial sites. We are confident that every investigator is doing the right thing by his or her Alphas and we are encouraged to see that several sites are open again for recruitment, securing that all rules and safeguarding are followed.
We would like to thank everyone involved in the research and development activities for setrusumab, alvelestat and our whole portfolio for your continued support and care for all people affected. For people involved in any of our trials, please speak directly to your physician if you have any questions, comments or concerns.
The OIFE and the OIF provide information for their members and all people in the OI community. And the Alpha-1 Foundation has created a dedicated information resource for Alphas and all those involved in the community.
The European Reference Network on Rare Bone Diseases, ERN-BOND, has also established a special section with resources on COVID-19, specifically aimed at patients and clinicians dealing with rare bone diseases. This brings together different European initiatives; together with a subsection containing worldwide COVID-19 guidelines and recommendations per country, developed by health experts and national authorities with the objective of providing immediate support to people with rare diseases affected by COVID-19.
We understand the high unmet medical need in both OI and Alpha-1 and in all the communities that we seek to serve; and we will be continuing to keep our development programmes moving forward in the best and most timely way possible. We will continue to do this in communication and close collaboration with the Alpha and OI communities, their treating physicians and the research communities across our portfolio.